Skip to main content

FDA Approvals

FDA Approvals, Payers' Guide
Welcome to the Eighth Annual Payers’ Guide to New FDA Approvals
Read More
Payers' Guide, FDA Approvals
Darzalex (Daratumumab) Approved as Part of a 3-Drug Regimen for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Defitelio (Defibrotide Sodium): First Drug Approved for Patients with Hepatic Veno-Occlusive Disease
Laura Morgan
Read More
Payers' Guide, FDA Approvals
Gazyva (Obinutuzumab) Approved for Patients with Rituximab-Refractory Follicular Lymphoma
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
Lisa A. Raedler, PhD, RPh
Read More
Page 32 of 53
Results 311 - 320 of 522